Healthcare / Medical DistributionJakarta
$440.00
-30.00 (-6.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $-63.5B · quality 18.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.45T
P/E
N/A
•EV/EBITDA
16.4x
↑ROE
-19.1%
↓Gross Margin
33.2%
↓Debt/Equity
3.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.0%
FCF CAGR
—
FCF margin
1.1%
FCF / Net income
-0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.22T · net income $-334.96B · FCF $101.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9223.33B | $9223.33B | $9938.96B | $9871.84B | $9232.68B |
| Net Income | $-334.96B | $-334.96B | $-842.27B | $-1964.16B | $-190.47B |
| EBITDA | $561.08B | $561.08B | $-174.92B | $-1328.85B | $717.06B |
| EPS | -60.17 | -60.17 | -151.31 | -353.14 | -34.25 |
| Gross Margin | 33.2% | 33.2% | 29.6% | 28.4% | 40.9% |
| Operating Margin | -1.9% | -1.9% | -8.4% | -16.9% | 5.0% |
| Net Margin | -3.6% | -3.6% | -8.5% | -19.9% | -2.1% |
| Balance Sheet | |||||
| Debt/Equity | 3.98 | 3.98 | 3.16 | 2.43 | 1.41 |
| Current Ratio | 0.71 | 0.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $101.03B | $101.03B | $-63.47B | $-1116.99B | $-503.25B |
| Returns | |||||
| ROE | -19.1% | -19.1% | -36.7% | -61.8% | -3.3% |
| Valuation | |||||
| EV/EBITDA | 16.36 | 16.36 | — | — | 16.71 |
| P/B | 1.47 | 1.47 | 1.66 | 2.45 | 1.05 |
| Growth & Yield | |||||
| Revenue Growth | -7.2% | -7.2% | 0.7% | 6.9% | — |
| EPS Growth | 60.2% | 60.2% | 57.2% | -931.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-151.31 → -60.17
Residual
-4.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.